BILLS-110hr3334ih.pdf

03:56 Aug 07, 2007 VerDate Aug 31 2005 1ST SESSION H. R. 3334 2003 annual 6 year 2 years later than 6 months 31 2005 3 years each year AUGUST 2, 2007

the ‘‘SMA Treatment

SMN1 the United States of America

Americans

SMA NIH SEC Institute of Neurological Disorders National the Centers for Disease Control National Institute of Child Health Health the National Center for Research Coordinating Committee the Coordinating Committee Health and Human Services NINDS Congress Control and Prevention the Best Pharmaceuticals Child Health the National Institutes of Health the National Institute of Child The SMA Project’s the Chair of the Coordinating Committee nating Committee the Orphan Drug Act the Committee on Energy and Commerce THE HOUSE OF REPRESENTATIVES Food and Drug Administration NIH COORDINATING COMMITTEE ON SMA A Food and Drug Administration the National Institute of Child 7 Health and Human Development the National Institute of NIH TRANS-INSTITUTE the Department of Edu- 24 Health Resources and Services Administration tional Institute of Neurological Disorders the Food and Drug Administration DRUG DEVELOPMENT PROMOTION the National Institute of Neurological AWARENESS ON SMA FOR HEALTH Services Administration the Chair of the Coordinating Com- House of Representa- Advisory Committee Institutes of Health ordinating Committee Health and Human Development SMA Project trans-National Institutes

CANTOR Duchenne Duchenne Muscular Dystrophy KENNEDY

muscular spinal disorders genetic disease treatments gene rapidly diseases drug dystrophy non profit stroke trials accelerate